Drug news
TAK 875 a new treatment for Type 2 Diabetes enters Phase III
TAK 875 from Takeda is a new selective agonist of the G-protein-coupled receptor (GPR 40)which is expressed in pancreatic islet beta cells. The drug has entered Phase III studies in Japan for Type 2 Diabetes and Phase III trials are commencing in the USA and EU. Phase II data showed a significant lower incidence of hypoglycaemia compared to placebo and to glimepiride and positive efficacy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.